Mohammed Rassool to Tenofovir
This is a "connection" page, showing publications Mohammed Rassool has written about Tenofovir.
Connection Strength
0,207
-
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial. Lancet HIV. 2017 11; 4(11):e486-e494.
Score: 0,133
-
Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine. AIDS. 2021 04 01; 35(5):759-767.
Score: 0,043
-
Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial. Lancet HIV. 2016 12; 3(12):e561-e568.
Score: 0,031